Skip Navigation

Phase III Study of Daratumumab/rHuPH20 NSC- 810307 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04071457

Study #:
STUDY00144570

Start Date:
Dec 25, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04071457

View Complete Trial Details & Eligibility at ClinicalTrials.gov